MAIA Biotechnology director receives 29,216 stock options at $1.53

MAIA Biotechnology director option grant reported MAIA Biotechnology, Inc. disclosed that director Stan V. Smith was granted stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan.

Rhea-AI Filing Summary

MAIA Biotechnology director option grant reported

MAIA Biotechnology, Inc. disclosed that director Stan V. Smith was granted stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The options cover 29,216 shares of common stock at an exercise price of $1.53 per share and vest 100% on the grant date, meaning they are exercisable beginning 12/31/2025.

The options have an expiration date of 12/31/2035. Following this grant, 29,216 derivative securities are shown as beneficially owned indirectly through The Stan V. Smith Trust Dated 1993.

Insider Trade Summary

Grant/Award: 29,216 shares

Grant/Award 1 txn

Insider Smith Stan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options	29,216	$0.00	$0.00

Holdings After Transaction: Options — 29,216 contracts (Indirect, See footnote)

Footnotes (2)

1. F1. The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
2. F2. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAIA (MAIA) report in this Form 4?

MAIA Biotechnology reported that director Stan V. Smith received a grant of 29,216 stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan.

What is the exercise price and term of the new MAIA stock options?

The granted stock options have an exercise price of $1.53 per share and an expiration date of 12/31/2035, giving the holder the right to buy MAIA common stock at that price until that date.

How do the MAIA options granted to Stan V. Smith vest?

The stock options granted on 12/31/2025 vest 100% on the grant date and are exercisable beginning as of that date, according to the explanation of responses.

How many MAIA derivative securities does Stan V. Smith beneficially own after this transaction?

After the reported transaction, 29,216 derivative securities (stock options) are listed as beneficially owned by Stan V. Smith.

How does Stan V. Smith hold his MAIA Biotechnology options?

The filing states that these securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993, and his ownership is reported as indirect.

What is Stan V. Smith’s relationship to MAIA Biotechnology, Inc.?

Stan V. Smith is identified as a director of MAIA Biotechnology, Inc. on the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/05/2026 - 08:42 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Stan

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	$1.53	12/31/2025		A		29,216		12/31/2025(1)	12/31/2035	Common Stock	29,216	$0	29,216	I(2)	See footnote

Explanation of Responses:

1. The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

2. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

	/s/ Stan V. Smith	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.